JP2020502252A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502252A5
JP2020502252A5 JP2019534721A JP2019534721A JP2020502252A5 JP 2020502252 A5 JP2020502252 A5 JP 2020502252A5 JP 2019534721 A JP2019534721 A JP 2019534721A JP 2019534721 A JP2019534721 A JP 2019534721A JP 2020502252 A5 JP2020502252 A5 JP 2020502252A5
Authority
JP
Japan
Prior art keywords
pyrrolo
pyridine
pyridin
quinoline
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019534721A
Other languages
English (en)
Japanese (ja)
Other versions
JP7134973B2 (ja
JP2020502252A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/067527 external-priority patent/WO2018119039A1/en
Publication of JP2020502252A publication Critical patent/JP2020502252A/ja
Publication of JP2020502252A5 publication Critical patent/JP2020502252A5/ja
Priority to JP2022133200A priority Critical patent/JP2022166286A/ja
Application granted granted Critical
Publication of JP7134973B2 publication Critical patent/JP7134973B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019534721A 2016-12-23 2017-12-20 Dyrk1aおよび/またはdyrk1bキナーゼの阻害剤としてのキノリンの誘導体 Active JP7134973B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022133200A JP2022166286A (ja) 2016-12-23 2022-08-24 Dyrk1aおよび/またはdyrk1bキナーゼの阻害剤としてのキノリンの誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16460096.7 2016-12-23
EP16460096 2016-12-23
PCT/US2017/067527 WO2018119039A1 (en) 2016-12-23 2017-12-20 Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022133200A Division JP2022166286A (ja) 2016-12-23 2022-08-24 Dyrk1aおよび/またはdyrk1bキナーゼの阻害剤としてのキノリンの誘導体

Publications (3)

Publication Number Publication Date
JP2020502252A JP2020502252A (ja) 2020-01-23
JP2020502252A5 true JP2020502252A5 (https=) 2021-01-28
JP7134973B2 JP7134973B2 (ja) 2022-09-12

Family

ID=57777491

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019534721A Active JP7134973B2 (ja) 2016-12-23 2017-12-20 Dyrk1aおよび/またはdyrk1bキナーゼの阻害剤としてのキノリンの誘導体
JP2022133200A Pending JP2022166286A (ja) 2016-12-23 2022-08-24 Dyrk1aおよび/またはdyrk1bキナーゼの阻害剤としてのキノリンの誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022133200A Pending JP2022166286A (ja) 2016-12-23 2022-08-24 Dyrk1aおよび/またはdyrk1bキナーゼの阻害剤としてのキノリンの誘導体

Country Status (6)

Country Link
US (1) US10577365B2 (https=)
EP (2) EP4183786A1 (https=)
JP (2) JP7134973B2 (https=)
LT (1) LT3558321T (https=)
PL (1) PL3558321T3 (https=)
WO (1) WO2018119039A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183786A1 (en) * 2016-12-23 2023-05-24 Felicitex Therapeutics, Inc. Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases
CN110483508B (zh) * 2019-08-29 2020-05-08 山东大学 化合物、制备方法及在制备GSK-3β抑制剂中的应用
EP4045908A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California Ex vivo tumor angiogenesis model
EP4045485A1 (en) 2019-10-18 2022-08-24 The Regents Of The University Of California 3-phenylsulphonyl-quinoline derivatives as agents for treating pathogenic blood vessels disorders
KR20230003981A (ko) * 2021-06-30 2023-01-06 한국화학연구원 DYRK1 억제제인 피롤로[3,2-c]피리딘 유도체 및 이의 용도
US20230192686A1 (en) * 2021-10-12 2023-06-22 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors
CN120904163B (zh) * 2025-10-09 2026-01-30 北京大学第一医院(北京大学第一临床医学院) 一种喹啉类化合物或其药学上可接受的盐及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1490364B1 (en) 2002-03-28 2007-09-26 Eisai R&D Management Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
TWI372624B (en) 2004-03-30 2012-09-21 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
US8778977B2 (en) * 2006-06-30 2014-07-15 Sunesis Pharmaceuticals, Inc. Pyridinonyl PDK1 inhibitors
JP2012511000A (ja) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション ホスホイノシチド依存性キナーゼ1(pdk1)の阻害剤
AU2011258465B2 (en) 2010-05-24 2016-12-15 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
ES2565627T3 (es) 2010-07-30 2016-04-06 Oncotherapy Science, Inc. Derivados de quinolina e inhibidores de MELK que contienen los mismos
US8362023B2 (en) 2011-01-19 2013-01-29 Hoffmann-La Roche Inc. Pyrazolo pyrimidines
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
CN103702998A (zh) 2011-07-05 2014-04-02 沃泰克斯药物股份有限公司 生产氮杂吲哚类的方法和中间体
CN103797002B (zh) 2011-08-19 2017-02-22 迪亚克森海特公司 Dyrk1抑制剂及其用途
EP2925319B1 (en) 2012-11-30 2019-01-09 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
WO2016000615A1 (en) * 2014-07-02 2016-01-07 Sunshine Lake Pharma Co., Ltd. Heteroaryl compounds and pharmaceutical applications thereof
EP4183786A1 (en) * 2016-12-23 2023-05-24 Felicitex Therapeutics, Inc. Derivatives of quinolines as inhibitors of dyrk1a and/or dyrk1b kinases

Similar Documents

Publication Publication Date Title
JP2020502252A5 (https=)
AU2004289672B2 (en) Inhibition of FGFR3 and treatment of multiple myeloma
US7825132B2 (en) Inhibition of FGFR3 and treatment of multiple myeloma
US9108963B2 (en) Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
TWI730959B (zh) 作為激酶抑制劑之雜環醯胺
CN101605787B (zh) 调节c-fms和/或c-kit活性的化合物及其应用
RU2338745C1 (ru) ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US20040092535A1 (en) Benzimidazole quinolinones and uses thereof
JP2016164184A5 (https=)
JP2012525431A5 (https=)
JP2005508313A5 (https=)
EP2477629A1 (en) Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
CA3124102C (en) Novel hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof
JP2011510985A5 (https=)
JP2017504652A5 (https=)
JP2020502252A (ja) Dyrk1aおよび/またはdyrk1bキナーゼの阻害剤としてのキノリンの誘導体
JP2019537581A5 (https=)
SI2864328T1 (en) Pharmaceutically active compounds
JP2019512534A5 (https=)
RU2018143284A (ru) Некоторые ингибиторы протеинкиназы
JP2019516790A5 (https=)
AU2015212495A1 (en) Antibacterial combinations comprising polymyxin
JP2021519294A5 (https=)
JP2009510162A5 (https=)
CN1976706B (zh) 抑制fgfr3及治疗多发性骨髓瘤